Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M.

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]

Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]

Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]